Two-Drug attack on Tough-to-Treat lymphoma

NCT ID NCT06563505

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

Summary

This study is testing whether combining two drugs, mosunetuzumab and zanubrutinib, is safe and effective for people with marginal zone lymphoma that has returned or hasn't responded to prior treatment. The trial will enroll 36 adults who have already tried at least one other therapy. Researchers will measure how well the combination shrinks tumors and controls the cancer over time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

LYMPHOMA